Natco Pharma Q1 results: Profit falls 57% to ₹206 cr, revenue at ₹735 cr | Company Results

Natco Pharma Ltd on Friday reported a 57 per cent decline in consolidated internet revenue at ₹206.5 crore within the first quarter ended June 2026, hit by decrease gross sales of its generic most cancers remedy drug lenalidomide.

The corporate had posted a consolidated internet revenue of ₹480.3 crore within the corresponding quarter final fiscal, Natco Pharma stated in a regulatory submitting.

Consolidated income from operations within the first quarter was decrease at ₹735.2 crore within the first quarter as in comparison with ₹ 1,328.9 crore within the corresponding interval a yr in the past, it added.

The decline is essentially attributable to decrease lenalidomide income within the present quarter, which was partially offset by progress within the base enterprise, the corporate stated.

Whole bills within the quarter beneath assessment had been decrease at ₹608.8 crore as in comparison with ₹818.7 crore in the identical interval a yr in the past, it added.

Within the first quarter, home pharmaceutical formulations income was at ₹136.4 crore, up from ₹107 crore within the year-ago interval.

However, worldwide formulations had a decrease income of ₹477.1 crore as towards ₹1,120.9 crore within the corresponding quarter final fiscal, Natco Pharma stated.

Energetic pharmaceutical elements (API) section clocked income of ₹66.7 crore within the first quarter as in comparison with ₹52.6 crore in the identical interval final fiscal, it added.

(Solely the headline and movie of this report might have been reworked by the Enterprise Commonplace workers; the remainder of the content material is auto-generated from a syndicated feed.)